Nirvana Life Sciences Inc. Stock Analysis NIRV.CN

Nirvana Life Sciences, Inc. engages in the research and development of therapeutic products derived from psychedelics. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2022-03-17. The firm is also focused on developing methodologies for standardized, quality-controlled extraction and purification of psychoactive compounds. The firm operates in a single reportable segment: research and development of therapeutic products that address addiction. The firm has selected two products for its first phase of development: a one-per-day slow-release gel cap that assists the transition from opioids to non-addictive pain relief therapies, and a one-per-day slow-release gel cap that delivers non-addictive pain relief. Any number of therapeutic medicines and products are created from its formulations. The company is also planning on growing several genera and species of fungi (including rare and hybrid varieties) with quality and batch consistency.